drugset

drugset / Trial / NCT02607215

Platinum Rechallenge in Patients With Platinum-sensitive mTNBC

NCT02607215 ↗

Phase 2 Unknown 84 enrolled Fudan University

RandomizedParallel-groupOpen-labelTreatment

Summary

Platinum Retreated in Patients with Platinum Sensitive mTNBC

Timeline

Start: 2015-11
Primary completion: 2022-12
Completion: 2022-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DDP	Unknown	75 mg/m2	—
Subject	Vinorelbine	Small molecule	25 mg/m2	—

Indications